XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Contingent Consideration (Details)

Commitments and Contingencies - Contingent Consideration (Details) - USD ($)					1 Months Ended	3 Months Ended	9 Months Ended
	Jan. 11, 2024	Jun. 21, 2023	Mar. 29, 2023	Oct. 06, 2021	Jun. 30, 2023	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Jun. 03, 2024	Apr. 03, 2024	Dec. 31, 2023
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs							$ 4,000,000				$ 7,000,000
Exarafenib milestone contingent consideration							3,125,000
Payments of consideration under RPAs, AAAs and CPPAs							37,000,000	$ 14,650,000
Changes in estimated fair value of contingent consideration								$ 75,000
Short-term royalty and commercial payment receivables							12,682,000				14,215,000
Long-term royalty and commercial payment receivables							54,207,000				57,952,000
Assignment and Assumption Agreement and Royalty Purchase Agreement \| LadRx
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs							1,000,000.0
Payments of consideration under RPAs, AAAs and CPPAs		$ 5,000,000.0
Long-term royalty and commercial payment receivables							1,000,000.0
Assignment and Assumption Agreement and Royalty Purchase Agreement \| LadRx \| Regulatory milestones
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs		$ 1,000,000.0				$ 0	0		$ 0		1,000,000.0
Payments of consideration under RPAs, AAAs and CPPAs	$ 1,000,000.0					1,000,000.0	1,000,000.0
Commercial Payment Purchase Agreement \| Aptevo
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs			$ 50,000
Payments of consideration under RPAs, AAAs and CPPAs			$ 9,600,000		$ 50,000
Short-term royalty and commercial payment receivables							2,200,000				2,000,000.0
Commercial Payment Purchase Agreement \| Affitech
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs						0
Payments of consideration under RPAs, AAAs and CPPAs				$ 6,000,000.0		6,000,000.0
Commercial Payment Purchase Agreement \| Affitech \| Regulatory milestones
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs				$ 8,000,000.0
Commercial Payment Purchase Agreement \| Affitech \| Sales-based milestones, first and second
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs						$ 0					6,000,000.0
Long-term royalty and commercial payment receivables											$ 6,000,000.0
Commercial Payment Purchase Agreement \| Affitech \| Sales-based milestones, third
Commitments And Contingencies
Contingent consideration under RPAs, AAAs and CPPAs							3,000,000.0
Short-term royalty and commercial payment receivables							3,000,000.0
CVR Agreement \| Kinnate CVR holders
Commitments And Contingencies
Exarafenib milestone contingent consideration							$ 3,100,000			$ 2,900,000